
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Finding and treating the underlying cause of sleep disturbance is critical to effective management. Here are a few medical conditions that may trigger key disrupting symptoms.




